Vistagen Therapeutics Stock Price To Book

VTGN Stock  USD 2.48  0.03  1.20%   
VistaGen Therapeutics fundamentals help investors to digest information that contributes to VistaGen Therapeutics' financial success or failures. It also enables traders to predict the movement of VistaGen Stock. The fundamental analysis module provides a way to measure VistaGen Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to VistaGen Therapeutics stock.
As of the 12th of December 2024, Price To Book Ratio is likely to drop to about (28.7 K).
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

VistaGen Therapeutics Company Price To Book Analysis

VistaGen Therapeutics' Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

P/B

 = 

MV Per Share

BV Per Share

More About Price To Book | All Equity Analysis

Current VistaGen Therapeutics Price To Book

    
  0.75 X  
Most of VistaGen Therapeutics' fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, VistaGen Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

VistaGen Price To Book Driver Correlations

Understanding the fundamental principles of building solid financial models for VistaGen Therapeutics is extremely important. It helps to project a fair market value of VistaGen Stock properly, considering its historical fundamentals such as Price To Book. Since VistaGen Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of VistaGen Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of VistaGen Therapeutics' interrelated accounts and indicators.
0.99-1.00.180.030.181.00.54-0.14-0.03-0.410.610.840.050.680.71-0.210.74-0.480.990.990.35
0.99-1.00.21-0.030.080.990.51-0.22-0.08-0.430.630.840.10.660.7-0.160.74-0.510.990.990.33
-1.0-1.0-0.190.03-0.12-1.0-0.530.210.050.42-0.6-0.83-0.07-0.66-0.720.17-0.750.51-0.99-0.99-0.36
0.180.21-0.190.06-0.220.180.090.06-0.18-0.590.270.250.140.190.230.160.29-0.380.150.150.07
0.03-0.030.030.060.540.020.20.360.18-0.020.170.23-0.340.080.05-0.330.240.050.01-0.010.12
0.180.08-0.12-0.220.540.180.290.660.450.04-0.120.13-0.440.270.2-0.440.090.220.170.190.27
1.00.99-1.00.180.020.180.53-0.14-0.04-0.410.610.830.060.660.7-0.20.72-0.470.990.990.34
0.540.51-0.530.090.20.290.53-0.20.22-0.25-0.140.32-0.220.270.88-0.20.55-0.330.480.50.95
-0.14-0.220.210.060.360.66-0.14-0.20.18-0.030.0-0.15-0.14-0.17-0.25-0.23-0.280.43-0.1-0.11-0.1
-0.03-0.080.05-0.180.180.45-0.040.220.18-0.28-0.19-0.06-0.930.010.230.330.07-0.35-0.08-0.060.24
-0.41-0.430.42-0.59-0.020.04-0.41-0.25-0.03-0.28-0.53-0.570.34-0.45-0.53-0.37-0.650.85-0.34-0.34-0.17
0.610.63-0.60.270.17-0.120.61-0.140.0-0.19-0.530.790.050.450.170.020.6-0.490.610.59-0.33
0.840.84-0.830.250.230.130.830.32-0.15-0.06-0.570.79-0.080.820.58-0.190.85-0.630.790.790.09
0.050.1-0.070.14-0.34-0.440.06-0.22-0.14-0.930.340.05-0.08-0.08-0.29-0.29-0.20.430.110.1-0.21
0.680.66-0.660.190.080.270.660.27-0.170.01-0.450.450.82-0.080.48-0.250.68-0.520.610.620.05
0.710.7-0.720.230.050.20.70.88-0.250.23-0.530.170.58-0.290.48-0.010.76-0.620.650.660.8
-0.21-0.160.170.16-0.33-0.44-0.2-0.2-0.230.33-0.370.02-0.19-0.29-0.25-0.01-0.06-0.43-0.2-0.2-0.09
0.740.74-0.750.290.240.090.720.55-0.280.07-0.650.60.85-0.20.680.76-0.06-0.760.660.660.36
-0.48-0.510.51-0.380.050.22-0.47-0.330.43-0.350.85-0.49-0.630.43-0.52-0.62-0.43-0.76-0.4-0.4-0.19
0.990.99-0.990.150.010.170.990.48-0.1-0.08-0.340.610.790.110.610.65-0.20.66-0.41.00.32
0.990.99-0.990.15-0.010.190.990.5-0.11-0.06-0.340.590.790.10.620.66-0.20.66-0.41.00.33
0.350.33-0.360.070.120.270.340.95-0.10.24-0.17-0.330.09-0.210.050.8-0.090.36-0.190.320.33
Click cells to compare fundamentals
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Competition

VistaGen Book Value Per Share

Book Value Per Share

(0.0513)

At this time, VistaGen Therapeutics' Book Value Per Share is very stable compared to the past year.
Based on the latest financial disclosure, VistaGen Therapeutics has a Price To Book of 0.7517 times. This is 97.07% lower than that of the Biotechnology sector and 87.55% lower than that of the Health Care industry. The price to book for all United States stocks is 92.1% higher than that of the company.

VistaGen Price To Book Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses VistaGen Therapeutics' direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of VistaGen Therapeutics could also be used in its relative valuation, which is a method of valuing VistaGen Therapeutics by comparing valuation metrics of similar companies.
VistaGen Therapeutics is currently under evaluation in price to book category among its peers.

VistaGen Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of VistaGen Therapeutics from analyzing VistaGen Therapeutics' financial statements. These drivers represent accounts that assess VistaGen Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of VistaGen Therapeutics' important valuation drivers and their relationship over time.
201920202021202220232024 (projected)
Market Cap19.3M183.5M245.5M25.1M22.5M21.4M
Enterprise Value22.0M84.1M180.4M11.1M10.0M9.5M

VistaGen Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, VistaGen Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to VistaGen Therapeutics' managers, analysts, and investors.
Environmental
Governance
Social

VistaGen Fundamentals

About VistaGen Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze VistaGen Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of VistaGen Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of VistaGen Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Pair Trading with VistaGen Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if VistaGen Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in VistaGen Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with VistaGen Stock

  0.87VALN Valneva SE ADRPairCorr
  0.84ERNA Eterna TherapeuticsPairCorr

Moving against VistaGen Stock

  0.78BMY Bristol Myers SquibbPairCorr
  0.72ESPR Esperion TherapeuticsPairCorr
  0.7DYAI Dyadic InternationalPairCorr
  0.5GILD Gilead SciencesPairCorr
  0.37DNA Ginkgo Bioworks HoldingsPairCorr
The ability to find closely correlated positions to VistaGen Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace VistaGen Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back VistaGen Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling VistaGen Therapeutics to buy it.
The correlation of VistaGen Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as VistaGen Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if VistaGen Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for VistaGen Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether VistaGen Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of VistaGen Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vistagen Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vistagen Therapeutics Stock:
Check out VistaGen Therapeutics Piotroski F Score and VistaGen Therapeutics Altman Z Score analysis.
To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.
You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VistaGen Therapeutics. If investors know VistaGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VistaGen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.74)
Revenue Per Share
0.029
Quarterly Revenue Growth
(0.34)
Return On Assets
(0.39)
Return On Equity
(0.62)
The market value of VistaGen Therapeutics is measured differently than its book value, which is the value of VistaGen that is recorded on the company's balance sheet. Investors also form their own opinion of VistaGen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is VistaGen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VistaGen Therapeutics' market value can be influenced by many factors that don't directly affect VistaGen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VistaGen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if VistaGen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VistaGen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.